 |
|
Adverse Effects of Cyclooxygenase 2 Inhibitors on Renal and Arrhythmia Events
Meta-analysis of Randomized Trials
Jingjing Zhang, MD, PhD;
Eric L. Ding, BA;
Yiqing Song, MD, ScD
JAMA. 2006;296:(doi:10.1001/jama.296.13.jrv60015).
Context Adverse effects of selective cyclooxygenase 2 (COX-2) inhibitors on renal events and arrhythmia have been controversial, with suggestions of a class effect.
Objective To quantitatively evaluate adverse risks of renal events (renal dysfunction, hypertension, and peripheral edema) and arrhythmia events and to explore drug class effects and temporal trends of apparent effects of the COX-2 inhibitors: rofecoxib, celecoxib, valdecoxib, parecoxib, etoricoxib, and lumiracoxib.
Data Sources A systematic search of EMBASE and MEDLINE (through June 2006), bibliographies, US Food and Drug Administration reports, and pharmaceutical industry clinical trial databases.
Study Selection From relevant reports, 114 randomized double-blind clinical trials were included.
Data Extraction Information on publication year, participant characteristics, trial duration, drug, control, dose, and events were extracted using a standardized protocol.
Data Synthesis Results were pooled via random-effects models and meta-regressions. Of 116 094 participants from 114 trial reports including 127 trial populations (40 rofecoxib, 37 celecoxib, 29 valdecoxib + parecoxib, 15 etoricoxib, and 6 lumiracoxib), there were a total of 6394 composite renal events (2670 peripheral edema, 3489 hypertension, 235 renal dysfunction) and 286 arrhythmia events. Results indicated significant heterogeneity of renal effects across agents (P for interaction = .02), indicating no class effect. Compared with controls, rofecoxib was associated with increased risk of arrhythmia (relative risk [RR], 2.90; 95% confidence interval [CI], 1.07-7.88) and composite renal events (RR, 1.53; 95% CI, 1.33-1.76); adverse renal effects increased with greater dose and duration (both P .05). For all individual renal end points, rofecoxib was associated with increased risk of peripheral edema (RR, 1.43; 95% CI, 1.23-1.66), hypertension (RR, 1.55; 95% CI, 1.29-1.85), and renal dysfunction (RR, 2.31; 95% CI, 1.05-5.07). In contrast, celecoxib was associated with lower risk of both renal dysfunction (RR, 0.61; 95% CI, 0.40-0.94) and hypertension (RR, 0.83; 95% CI, 0.71-0.97) compared with controls. Other agents were not significantly associated with risk. Time-cumulative analyses indicated that for rofecoxib the adverse risks for peripheral edema and hypertension were evident by the end of year 2000 and for risk of arrhythmia by 2004.
CONCLUSIONS In this comprehensive analysis of 114 randomized trials with 116 094 participants, rofecoxib was associated with increased renal and arrhythmia risks. A COX-2 inhibitor class effect was not evident. Future safety monitoring is warranted and may benefit from an active and continuous cumulative surveillance system.
Published online: September 12, 2006 (doi:10.1001/jama.296.13.jrv60015).
Author Affiliations: Renal Division (Dr Zhang) and Division of Preventive Medicine (Mr Ding and Dr Song), Brigham and Women's Hospital and Harvard Medical School, Boston, Mass; Departments of Epidemiology and Nutrition (Mr Ding), Harvard School of Public Health, Boston, Mass.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLES
COX-2 Inhibitors, Other NSAIDs, and Cardiovascular Risk: The Seduction of Common Sense
David J. Graham
JAMA. 2006;296(13):1653-1656.
EXTRACT
| FULL TEXT
Cardiovascular Risk and Inhibition of Cyclooxygenase: A Systematic Review of the Observational Studies of Selective and Nonselective Inhibitors of Cyclooxygenase 2
Patricia McGettigan and David Henry
JAMA. 2006;296(13):1633-1644.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Chemopreventive Efficacy of Naproxen and Nitric Oxide-naproxen in Rodent Models of Colon, Urinary Bladder, and Mammary Cancers
Steele et al.
Cancer Prevention Research 2009;2:951-956.
ABSTRACT
| FULL TEXT
Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program
Krum et al.
Eur J Heart Fail 2009;11:542-550.
ABSTRACT
| FULL TEXT
Cardiomyocyte cyclooxygenase-2 influences cardiac rhythm and function
Wang et al.
Proc. Natl. Acad. Sci. USA 2009;106:7548-7552.
ABSTRACT
| FULL TEXT
Prostanoids in health and disease
Smyth et al.
J. Lipid Res. 2009;50:S423-S428.
ABSTRACT
| FULL TEXT
Controlling for Drug Dose in Systematic Review and Meta-Analysis: A Case Study of the Effect of Antidepressant Dose
Hansen et al.
Med Decis Making 2009;29:91-103.
ABSTRACT
The Cardiovascular Research Network: A New Paradigm for Cardiovascular Quality and Outcomes Research
Go et al.
Circ Cardiovasc Qual Outcomes 2008;1:138-147.
ABSTRACT
| FULL TEXT
Hypertension in rheumatoid arthritis
Panoulas et al.
Rheumatology (Oxford) 2008;47:1286-1298.
ABSTRACT
| FULL TEXT
Acupuncture and related techniques for postoperative pain: a systematic review of randomized controlled trials
Sun et al.
Br J Anaesth 2008;101:151-160.
ABSTRACT
| FULL TEXT
Use of Common Medications and Breast Cancer Risk
Moysich et al.
Cancer Epidemiol. Biomarkers Prev. 2008;17:1564-1595.
ABSTRACT
| FULL TEXT
Nonaspirin NSAIDs, Cyclooxygenase 2 Inhibitors, and the Risk for Stroke
Roumie et al.
Stroke 2008;39:2037-2045.
ABSTRACT
| FULL TEXT
Celecoxib modulates hypertrophic signalling and prevents load-induced cardiac dysfunction
Jacobshagen et al.
Eur J Heart Fail 2008;10:334-342.
ABSTRACT
| FULL TEXT
Cyclooxygenase-2 Inhibitors and Most Traditional Nonsteroidal Anti-inflammatory Drugs Cause Similar Moderately Increased Risks of Cardiovascular Disease
Hennekens and Borzak
J CARDIOVASC PHARMACOL THER 2008;13:41-50.
ABSTRACT
Perioperative Versus Postoperative Celecoxib on Patient Outcomes After Major Plastic Surgery Procedures
Sun et al.
Anesth. Analg. 2008;106:950-958.
ABSTRACT
| FULL TEXT
Review: Adverse cardiovascular effects of NSAIDs: driven by blood pressure, or edema?
Aneja and Farkouh
Ther Adv Cardiovasc Dis 2008;2:53-66.
ABSTRACT
Nonsteroidal Anti-inflammatory Drugs and Cyclooxygenase-2 Inhibitors for Primary Prevention of Colorectal Cancer: A Systematic Review Prepared for the U.S. Preventive Services Task Force
Rostom et al.
ANN INTERN MED 2007;146:376-389.
ABSTRACT
| FULL TEXT
The patient, the drug and the kidney
DTB 2006;44:89-95.
ABSTRACT
| FULL TEXT
Emerging Mechanisms of Immunosuppression in Oral Cancers
Jewett et al.
JDR 2006;85:1061-1073.
ABSTRACT
| FULL TEXT
COX-2 Inhibitors and NSAIDs: More Data on CV Risk
Journal Watch Cardiology 2006;2006:2-2.
FULL TEXT
COX-2 Inhibitors, Other NSAIDs, and Cardiovascular Risk: The Seduction of Common Sense
Graham
JAMA 2006;296:1653-1656.
FULL TEXT
|
